期刊文献+

口服阿法骨化醇冲击治疗高龄血液透析患者继发性甲状旁腺功能亢进 被引量:6

Alfacalcidol oral pulse therapy in aged hemodialysis patients with secondaryhyperparathyroidism
原文传递
导出
摘要 目的比较阿法骨化醇口服冲击与每日口服两种方法治疗维持性血液透析(血透)患者继发性甲状旁腺功能亢进的疗效及安全性。方法将89例高龄维持性血透患者随机分为口服冲击组(45例,予阿法骨化醇每次1μg~4μg,每周2次)和每日口服组(44例,予阿法骨化醇0.25μg·d^(-1))。比较2组患者治疗前及治疗4、8 wk后的甲状旁腺素(iPTH)、血钙及血磷的水平变化。结果 2组iPTH水平均较治疗前明显下降(均P<0.01);口服冲击组在治疗4 wk和8 wk时总达标率分别为80%、96%,明显高于每日口服组(48%、70%,均P<0.01);口服冲中击组治疗前iPTH为500~1 000 ng·L^(-1)的患者于治疗后4 wk的达标率为90%明显高于每日口服组(45%,P<0.01);2组血钙、磷水平均有上升,与治疗前比较以每日口服组较为明显(P<0.01)。结论阿法骨化醇每日口服常规剂量和口服冲击两种疗法都能有效控制高龄血透患者继发性甲状旁腺功能亢功能,安全性良好;而冲击治疗见效快,疗效更显著。
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2012年第10期623-626,共4页 Chinese Journal of New Drugs and Clinical Remedies
基金 浙江省瑞安市科技计划项目(201002078)
关键词 肾透析 甲状旁腺功能亢进症 阿法骨化醇 冲击治疗 renal dialysis hyperparathyroidism alfaealcidol pulse therapy
  • 相关文献

参考文献9

二级参考文献29

  • 1章俊,李幼姬,叶任高.血液透析患者甲状旁腺素和血小板胞内游离钙变化及相互关系[J].中华肾脏病杂志,1996,12(5):269-272. 被引量:3
  • 2刘忠厚 马述仕 王石麟 等.现代临床医学丛书 第1版[M].北京:科学出版社,1998.237.
  • 3CHEN M, CHOW SN. Additive effect of alfacalcidol on bone mineral density of the lumbar spine in Taiwan Residents postmenopausal women treated with hormone replacement therapy and calcium supplementation: a randomized 2-year study [J]. Clin Endocrinol, 2001,55(2) : 253-258.
  • 4KANIS JA. Osteoporosis. 1st ed [ M]. London: Blackwell Science Publishing House, 1994. 5-7.
  • 5SAISU T, WAKABAYASHI Y, YAMADA K, et al. Effect of low-calcium hemodialysate on bone metabolism [J ]. J Bone Miner Metab, 2000, 18(2):57-62.
  • 6GILLESPIE WJ, HENRY DA, O'CONNELL DL, et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis [ DB/OL].Cochrane Database Syst Rev, 2000, (2) : CD000227.
  • 7TANIZAWA T, IMURA K, ISHII Y, et al. Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures: a retrospective study [J]. Osteoporos Int,1999,9(2) : 163-170.
  • 8ZHAN Z, YAMAMOTO I , MORTIA R. Urinary pyridinoline and deoxypyridinoline as bone metabolic markers in predicting therapeutic effects of estrogen and alfacaleidol in women with osteoporosis[J]. J Bone Miner Metab, 1999,17(2): 113-118.
  • 9GORAI I, CHAKI O, TAGUCHI Y, et al. Early postmenopausal bone loss is prevented by estrogen and partially by lalpha-OH-vita-min D3: therapeutic effects of estrogen and/or lalpha-OH-vitamin D3[J]. Calcif Tissue Int, 1999, 65(1): 16-22.
  • 10Yudd M,Llach F. Renal Osteodystrophy. In:Owen WF,Pereim BJG and Sayegh MH, Dialysis and Transplantation, 1 st edition, W. B. Saunders,2000.253-279.

共引文献35

同被引文献65

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部